Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus ZEVTERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus ZEVTERA.
CEFUROXIME SODIUM IN PLASTIC CONTAINER vs ZEVTERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a beta-lactam cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible organisms.
Ceftobiprole, the active moiety of ZEVTERA, is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), leading to cell death.
1.5 g IV every 8 hours for moderate to severe infections; may be increased to 3 g IV every 8 hours for severe or life-threatening infections.
400 mg intravenously every 8 hours
None Documented
None Documented
Terminal elimination half-life: 1.2-1.9 hours. Prolonged in renal impairment (up to 15-20 hours with CrCl <20 mL/min).
Terminal elimination half-life is approximately 3.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to ~6 hours, requiring dose adjustment.
Renal excretion: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Approximately 70% of the dose is excreted unchanged in urine, with 20% recovered in feces via biliary elimination. Minor route: <5% as metabolites.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic